Biopharma Plasma LLC

Quick facts

Phase 3 pipeline

• BP-SCIG 20% · Immunology
  BP-SCIG 20% is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering immunoglobulin G (IgG) antibodies to patients with primary immunodeficiency.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biopharma Plasma LLC portfolio CI brief
• Biopharma Plasma LLC pipeline updates RSS